MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/shk.0000000000002315

Медицинская библиотека · Shock (Augusta, Ga.) · 2024

HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL.

Kyriazopoulou Evdoxia, Dalekos George N, Metallidis Symeon, Poulakou Garyphalia, Papanikolaou Ilias C, Tzavara Vasiliki, Argyraki Katerina, Alexiou Zoi, Panagopoulos Periklis, Samarkos Michael, Chrysos George, Tseliou Aikaterini, Milionis Haralampos, Sympardi Styliani, Vasishta Anil, Giamarellos-Bourboulis Evangelos J

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

We aimed to evaluate heparin-binding protein (HBP) as a marker of prognosis of unfavorable outcome in COVID-19 pneumonia. This was a post hoc analysis of the SAVE clinical trial investigating anakinra treatment, guided by suPAR (soluble urokinase plasminogen activator receptor) levels ≥6 ng/mL, for the prevention of severe respiratory failure in hospitalized patients with COVID-19 pneumonia. Baseline HBP plasma levels were measured in 534 patients by fluorescence dry quantitative immunoassay using the Jet-iStar 800 analyzer. Concentrations higher than 35 ng/mL predicted 30-day mortality with a moderate specificity of 53.3% and negative predictive value 78.1%; sensitivity was low (29.0%). After multivariate Cox analysis, HBP higher than 35 ng/mL was an independent predictor of 30-day unfavorable outcome (adjusted hazard ratio, 1.77; 95% CI, 1.06-2.94; P = 0.028) and these patients were also at greater risk of death after 90 days (hazard ratio, 1.85; 95% CI, 1.25-2.74; P = 0.002). The cutoff was not predictive of development of severe respiratory failure, septic shock or acute kidney injury. Among patients with baseline HBP levels higher than 35 ng/mL, anakinra treatment was associated with decreased mortality (7.2%) versus comparators (18.1%; P < 0.001). Results confirm that HBP may be an early biomarker of poor outcome among preselected patients at risk from COVID-19 pneumonia.ClinicalTrials.gov registration NCT04357366.

Для цитирования: Kyriazopoulou Evdoxia, Dalekos George N, Metallidis Symeon, Poulakou Garyphalia, Papanikolaou Ilias C, Tzavara Vasiliki, Argyraki Katerina, Alexiou Zoi, Panagopoulos Periklis, Samarkos Michael, Chrysos George, Tseliou Aikaterini, Milionis Haralampos, Sympardi Styliani, Vasishta Anil, Giamarellos-Bourboulis Evangelos J. HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL.. Shock (Augusta, Ga.). 2024. DOI: 10.1097/shk.0000000000002315.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.